Gout: Diagnosis and treatment.

[1]  G. Gamble,et al.  Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study , 2015, Annals of the rheumatic diseases.

[2]  H. Schumacher,et al.  Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions , 2012, Annals of the rheumatic diseases.

[3]  H. Schumacher,et al.  Febuxostat compared with allopurinol in patients with hyperuricemia and gout. , 2005, The New England journal of medicine.

[4]  J. Sánchez-Payá,et al.  Silent Monosodium Urate Crystal Deposits Are Associated With Severe Coronary Calcification in Asymptomatic Hyperuricemia: An Exploratory Study , 2016, Arthritis & rheumatology.

[5]  M. González-Gay,et al.  An Audit of the Variability of Diagnosis and Management of Gout in the Rheumatology Setting: The Gout Evaluation and Management Study , 2011, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[6]  F. Perez-Ruiz,et al.  Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout , 1998, Annals of the rheumatic diseases.

[7]  R. Terkeltaub,et al.  High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. , 2010, Arthritis and rheumatism.

[8]  E. Martı́n-Mola,et al.  Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study , 2011, Annals of the rheumatic diseases.

[9]  W. Taylor,et al.  Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. , 2012, Arthritis and rheumatism.

[10]  D. Loeuille,et al.  Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. , 2007, The Journal of rheumatology.

[11]  C. Bombardier,et al.  Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative , 2013, Annals of the rheumatic diseases.

[12]  W. Willett,et al.  Alcohol intake and risk of incident gout in men: a prospective study , 2004, The Lancet.

[13]  R. Terkeltaub,et al.  2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis , 2012, Arthritis care & research.

[14]  H. Schumacher,et al.  Clinical Diagnostic Criteria for Gout: Comparsion With the Gold Standard of Synovial Fluid Crystal Analysis , 2009, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[15]  Charles King,et al.  2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia , 2012, Arthritis care & research.

[16]  E. Pascual,et al.  Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout , 2007, Annals of the rheumatic diseases.

[17]  F. Becce,et al.  2016 updated EULAR evidence-based recommendations for the management of gout , 2014, Annals of the rheumatic diseases.

[18]  F. Perez-Ruiz,et al.  Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. , 2002, Arthritis and rheumatism.

[19]  C. Weel,et al.  Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial , 2008, The Lancet.

[20]  S. Chohan.  Safety and Efficacy of Febuxostat Treatment in Subjects with Gout and Severe Allopurinol Adverse Reactions , 2011, The Journal of Rheumatology.

[21]  I. Reid,et al.  Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial , 2012, Annals of the rheumatic diseases.

[22]  D. M. van der Heijde,et al.  EULAR/EFORT recommendations for the diagnosis and initial management of patients with acute or recent onset swelling of the knee , 2009, Annals of the rheumatic diseases.

[23]  E. Batlle-Gualda,et al.  Synovial Fluid Analysis for Diagnosis of Intercritical Gout , 1999, Annals of Internal Medicine.

[24]  M. Cravets,et al.  Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol , 2016, Annals of the rheumatic diseases.

[25]  R. Day,et al.  A Benefit-Risk Assessment of Benzbromarone in the Treatment of Gout , 2008, Drug safety.

[26]  M. A. van de Laar,et al.  A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout , 2008, Annals of the rheumatic diseases.

[27]  M. Goldacre,et al.  Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. , 2013, Rheumatology.

[28]  H. Schumacher,et al.  Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. , 2008, Arthritis and rheumatism.